Incyte Stock News

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2025. The schedule for the press release and conference call/webcast is as follows: Q3 2025 Press Release: October 28, 2025 at 7:00 a.m. ET Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET ...

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...

SHENZHEN, CHINA, Sept. 28, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by C...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025.  “Sometimes, it can feel like there's nothing left to buy,” the former hedge fund manager agreed in a recent segment of Mad Money.

Even as the indexes soar to new heights, CNBC's Jim Cramer said investors can still find relatively inexpensive names. "Sometimes it can feel like there's nothing left to buy," he said.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer.

There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.